Related Experiment Video

Updated: Apr 20, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.4K

Moxifloxacin is not anti-inflammatory in experimental pneumococcal pneumonia

H C Müller-Redetzky1, S M Wienhold1, J Berg1

  • 1Department of Infectious Diseases and Pulmonary Medicine, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.

The Journal of Antimicrobial Chemotherapy
|November 20, 2014
PubMed
Abstract

Insights

Moxifloxacin did not show significant anti-inflammatory effects in pneumococcal pneumonia models. While it reduced bacterial load and vascular permeability, it did not alter key inflammatory markers or lung injury compared to ampicillin.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Immunology

Background:

  • Antibiotics possess anti-inflammatory properties that may mitigate hyperinflammation in pneumonia.
  • Moxifloxacin is reported to have immunomodulatory effects, but evidence in pneumonia is limited.

Purpose of the Study:

  • To investigate moxifloxacin's anti-inflammatory effects in pneumococcal pneumonia.
  • To compare moxifloxacin with ampicillin regarding pulmonary and systemic inflammation and lung injury.

Main Methods:

  • Utilized ex vivo human lung tissue and in vivo mouse models of pneumococcal pneumonia.
  • Assessed local inflammatory response, bacterial growth, clinical course, leukocyte dynamics, vascular permeability, lung pathology, and systemic inflammation.
  • Quantified endothelial monolayer integrity in vitro.

Main Results:

  • Moxifloxacin reduced cytokine production in TNF-α-stimulated lung tissue but not in pneumococci-infected tissue.
  • In vivo, moxifloxacin decreased bacterial load more than ampicillin but did not differ in inflammatory parameters or lung pathology.
  • Moxifloxacin-treated mice showed reduced pulmonary vascular permeability, but no direct barrier-stabilizing effects were observed.

Conclusions:

  • Experimental data do not support moxifloxacin having potent anti-inflammatory properties in pneumococcal pneumonia.
  • Moxifloxacin's primary benefit in this model appears to be antibacterial rather than anti-inflammatory.
Keywords:
Streptococcus pneumoniaeacute lung injuryantibioticsinflammation

More Related Videos

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

7.9K
Experimental Human Pneumococcal Carriage07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.4K

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
72
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
4.6K
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
16
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.4K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
768